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Abstract
Background In colon cancer, the location and density of tumor-infiltrating lymphocytes (TILs) can classify patients into low 
and high-risk groups for prognostication. While a commercially available ‘Immunoscore®’ exists, the incurred expenses and 
copyrights may prevent universal use. The aim of this study was to develop a robust and objective quantification method of 
TILs in colon cancer.
Methods A consecutive, unselected series of specimens from patients with colon cancer were available for immunohisto-
chemistry and assessment of TILs by automated digital pathology. CD3 + and CD8 + cells at the invasive margin and in tumor 
center were assessed on consecutive sections using automated digital pathology and image analysis software  (Visiopharm®). 
An algorithm template for whole slide assessment, generated cell counts per square millimeters (cells/mm2), from which 
the immune score was calculated using distribution volumes. Furthermore, immune score was compared with clinical and 
histopathological characteristics to confirm its relevance.
Results Based on the quantified TILs numbers by digital image analyses, patients were classified into low (n = 83, 69.7%), 
intermediate (n = 14, 11.8%) and high (n = 22, 18.5%) immune score groups. High immune score was associated with stage 
I–II tumors (p = 0.017) and a higher prevalence of microsatellite instable (MSI) tumors (p = 0.030). MSI tumors had a sig-
nificantly higher numbers of CD3 + TILs in the invasive margin and CD8 + TILs in both tumor center and invasive margin, 
compared to microsatellite stable (MSS) tumors.
Conclusion A digital template to quantify an easy-to-use immune score corresponds with clinicopathological features and 
MSI in colon cancer.
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Introduction
Colorectal cancer (CRC) is a leading cause to the cancer bur-
den and cancer deaths worldwide. Despite improvements in 
surgical and oncological management over the last decade [1], 
about half of all patients will develop metastasis and eventually 
die from disseminated disease [2]. The Tumor–node–metasta-
ses system (TNM classification) used for staging and prognos-
tication is imperfect in its ability to correctly guide treatment 
and define appropriate subgroups beyond surgical treatment 
[3]. The TNM system largely dependent on using the node sta-
tus to guide further adjuvant treatment, and as a consequence 
there is ongoing risk for under- and overtreatment of patients, 
based on the current guidelines for adjuvant chemotherapy 
[4, 5].
Of note, emerging data suggest the role of molecular sub-
types with distinct features and associated outcomes [6, 7]. 
Among the suggested consensus molecular subtypes is the 
“immunogenic” type, which is associated with hypermuta-
tion, microsatellite instability (MSI) and a favorable prog-
nosis. Abundant immune cells are found in the vicinity of 
such tumors and the type, density and location of the immune 
cells within tumor samples strongly influence the evolution 
of CRCs [8, 9] with impact on prognosis reported in large, 
multicenter studies [10–12]. This adaptive immune response 
of T-cells in tumor has been quantified as a measure called 
“Immunoscore®” (HalioDx, Marseille, France) [11, 13], and 
is available commercially as a test [14]. However, the costs 
implied with the commercially available assay may be pro-
hibitive in a public health care setting and/or may currently 
not be reimbursed for clinical routine use. More widespread 
use of immune scoring could be available if easy, accessible 
and low-cost methods would allow for stratification of immu-
nogenic tumors. Moreover, manual and subjective assessment 
such as counting cells, is increasingly being replaced by digi-
tal pathology in routine practice in departments of pathology 
[15, 16]. The benefits of digital pathology include objective 
measurement on regular slides [17] with a quantitative read of 
how many cells of interest are present in an area using immu-
nostained sample slides. The highly objectivity and quantita-
tive approach makes it easier to compare high number of tissue 
slides from patients and correlate to disease outcome.
The aim of this study was to establish an objective and 
highly reproducible quantification method for tumor-infil-
trating lymphocytes (TILs) in colon cancer and to correlate 




Patients were recruited from an ongoing prospective, clin-
ical-molecular biomarker outcomes study, the ACROBAT-
ICC project [18] (clinicaltrials.gov ID: NCT01762813). 
This cohort study is reported according to the STROBE 
[19] and the REMARK [20] guidelines for biomarker 
studies.
Compliance with ethical standards
The study is conducted in accordance to national regulations 
and approved by the Norwegian Regional Ethics Committee 
(REK Helse Vest, #2012/742). All procedures performed 
in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national 
research committee and with the 1964 Helsinki Declaration 
and its later amendments or comparable ethical standards.
Informed consent
Written informed consent was obtained from all partici-
pants prior to inclusion in the study.
Study population
All patients were diagnosed, managed and followed-up 
at Stavanger University Hospital (SUH), a public-funded 
university hospital within the universal health care sys-
tem of Norway. The protocol [18] and study cohort have 
been described in further detail elsewhere [21, 22]. The 
current study is based on patients with stage I–III colon 
cancer from the initial cohort recruited between January 
2013 and May 2014 [21] that did not undergo neoadju-
vant treatment. Of 132 consecutive stage I–III colon can-
cers, 119 were included in the study. Patients with two or 
more invasive colon carcinomas at time of surgery were 
excluded from the study, as these tumors might have a 
different biology [23]. When multiple tumor blocks were 
present, the tumor block that included invasive margin and 
most immune cells was selected for analysis [24].
Histopathology
All specimens were staged (AJCC 8th edition) [25, 26] 
by board certified pathologists using a standardized gross 
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pathology and microscopic histopathology template for 
reporting.
Immunohistochemistry
Antigen retrieval and antibody dilution were optimized prior 
to the study onset. Adjacent to the hematoxylin–eosin (H&E) 
stained sections, consecutive 2 µm paraffin sections were cut 
and mounted onto Superfrost Plus slides (Menzel, Braun-
schweig, Germany), along the principles suggest previously 
[27]. The CD3 and CD8 slides were incubated at 60 °C for 
1 h and then placed in the autostainer (Dako Omnis), where 
they were subject to an automated protocol as per manufac-
turer instructions, with a pretreatment at 97 °C in 30 min. 
CD3 (Dako Clone F7.2.38) was diluted with Dako Antibody 
diluent by 1:75 and CD8 (Dako Clone C8/144B) by 1:50. A 
peroxidase detection kit (Envision substrate working solu-
tion, Dako, Glostrup, Denmark) visualized the immune com-
plex for all the antibodies. Sections were then counterstained 
with hematoxylin in the Dako Omnis stainer. Afterwards, the 
slides were dehydrated and mounted manually.
Digital pathology assessment
CD3- and CD8-stained slides were scanned at 40 × mag-
nification using Leica SCN400 slide scanner (Leica 
Microsystems, Wetzlar, Germany) and uploaded to image 
analysis software,  Visiopharm® (Hoersholm, Denmark). 
The region of tumor center (TC) and invasive margin (IM) 
were marked manually on whole slides in  Visiopharm® 
Fig. 1  a Hematoxylin–eosin staining of tumor. b Immunohisto-
chemical staining of CD3 (brown) in the same tumor with marking 
of tumor center/TC (blue) and invasive margin/IM (green). c Digital 
image analysis measured the CD3 + tumor-infiltrating lymphocytes 
(TILs) in TC and IM. The number of positive TILs was calculated pr. 
 mm2. The same tumor area was analyzed for CD3 and CD8 for each 
patient. d Close-up view that shows positive TILs marked with green. 
Negative nuclei are marked blue and surrounding stroma is marked 
red
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and these regions (region of interest, ROI) were used for 
CD3 + and CD8 + cell quantification (Fig. 1).  Visiopharm® 
identified and measured the area of positive cells (µm) 
using digital image analysis (DIA). After DIA, the area 
of positive cells were transformed into number of positive 
TILs based on the estimation of mean area of a lympho-
cyte (60 µm2). The number of positive CD3 + and  CD8+ 
TILs was calculated per square millimeters (n cells/mm2) 
[28], further represented as density of cells.
Unspecified stains and artefacts were removed manu-
ally using the image software. Application in the image 
software was adjusted for detection of different immune 
stain intensity.
Immune response was calculated based on mean den-
sities of CD3 + and CD8 + in TC and IM in all of the 
patients in the study. The calculated mean density was 
used to divide the individual cases into “high” or “low” 
immune response. Cases with mean density ≥ 75-percen-
tile were regarded as “high” immune response. Patients 
were stratified from I0 to I4 according to the “Immu-
noscore®”, based on the total number of observed high 
densities  (CD3+ TILs and  CD8+ TILs in TC and IM) [11, 
13]. The final immune score was categorized based on 
mean percentiles for all four markers, and divided into 
immune score “low”, “intermediate” and “high” based on 
the number of markers (0–4) ≥ 75th percentile (Fig. 2).
Histopathological parameters
Histopathological parameters were registered from the 
pathology report including mucinous component, lympho-
vascular infiltration and lymph node status. In addition, 
tumor budding was registered in the HE section with deepest 
infiltration according to recommended guidelines [29, 30].
Analysis of microsatellite instability
Analysis of MSI has been described previously [31, 32]. 
Briefly, FFPE blocks were selected by an experienced 
pathologist (DL) and 4 × 10  μm sections were cut at a 
microtome. Automated DNA extraction was carried out 
using AllPrep DNA/RNA FFPE kit (Qiagen, Hilden, Ger-
many) on a QiaCUBE instrument (Qiagen) according to 
manufacturer’s instructions. Nucleic acid concentration and 
purity were measured on a NanoDrop 2000 (ThermoFischer 
scientific, Waltham, USA). Multiplex PCR reactions (one for 
each MSI) were set up for tumor and normal DNA in each 
patient. TypeIT microsatellite (Qiagen) master mix, together 
with a blending of 5 × 5′-fluorescently labelled primer pairs 
was used for each reaction. PCR conditions were as follows: 
5′ at 95 °C (initial denaturation and enzyme activation), fol-
lowed by 37 cycles of 30″ at 95 °C (denaturation), 90″ at 
55 (MSI) and 30″ at 72 °C (extension). A final extension 
step for 30′ at 60 °C. The primers for MSI were specific for 
Fig. 2  Flowchart for calculating immune response based on mean densities of CD3 + and CD8 + in tumor center (TC) and invasive margin (IM)
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BAT-25, BAT-26, NR-21, NR-24 and NR-27 [33, 34], which 
are all quasimonomorphic mononucleotide repeats with a 
high fidelity to high-frequency MSI, as shown previously 
[32]. To define a tumor as MSI, at least 2/5 markers needed 
to be unstable in their panels.
Statistics
IBM SPSS Statistics for Windows, Version 26.0 (IBM Cor-
poration, Armonk, NY, USA) was used for statistical analy-
sis. Associations between categorical variables were tested 
with Chi-square. Mann–Whitney U test was used to com-
pare differences in continuous or ordinal variables between 
groups. All tests were two-tailed and a p value < 0.050 was 
determined as statistically significant.
Results
The study cohort included 119 stage I–III colon cancer 
patients that underwent surgery with curative intent. Patient 
characteristics is presented in Supplement Table 1. Accord-
ing to the TNM classification, the distribution between stage 
I–III were approximately equal (31%, 36% and 32%, respec-
tively). Slightly more women were noted in the cohort, oth-
erwise the distributions were as expected for a consecutive 
cohort of colon cancer, with lymph node status, tumor size, 
histological type and grade, and overall age.
Distribution of the number of CD3 + and CD8 + TILs 
in TC and IM is presented in Fig. 3. The number of TILs 
was higher in IM compared with TC, both for CD3 + and 
CD8 + cells. Percentiles for evaluating immune response 
based on density (cells/mm2) of CD3 and CD8 is presented 
in Table 1. The total numbers of cells/mm2 counted in 
the upper range (75th percentile) were almost double in 
the invasive margin compared to tumor center, for both 
CD3 + and CD8 + cells, respectively. Table 2 shows dis-
tribution of cases with high immune response (≥ 75th 
percentile) in the different regions. These results were 
summarized to calculate immune score, which is pre-
sented in Table 3. According to the immune score set up 
(Table 3), there number of patients in the immune score 
groups of low, intermediate and high was 83 (69.7%), 14 
(11.8%) and 22 (18.5%), respectively. Hence, two-thirds 
of the colon cancers were deemed immune-low, with the 
immune-high cases split even between a three of four and 
four of four regions marked as immune high.
Fig. 3  Distribution of number of CD3 + and CD8 + TILs in tumor center (TC) and invasive margin (IM)
Table 1  Density (cells/mm2) cut-off values based on highest quartiles 
(75th percentile)
Tumor center Invasive margin
CD3 + CD8 + CD3 + CD8 + 
cells/mm2 cells/mm2 cells/mm2 cells/mm2
Median 393 220 858 513
Percentiles 25th 187 112 452 277
50th 393 220 858 513
75th 760 466 1390 896
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Higher immune scores were associated with a higher 
frequency of stage I–II tumors (p = 0.017) and a higher 
prevalence of MSI tumors (p = 0.030), compared with 
tumors from intermediate and low immune score. Three of 
22 patients with high immune score had stage III disease, 
whereas for stage I and II the number was 12 and 7, respec-
tively. For patients with low immune score, 19 were stage 
I, 34 stage II and 30 stage III. For intermediate immune 
score, the corresponding number of patients were 6 stage I, 
2 stage II and 6 stage III. Twelve of 42 MSI tumors (28.6%) 
had high immune score and 10 of 77 microsatellite stabile 
(MSS) tumors (13.0%) had a high immune score, respond-
ing to twofold increase of immune-high cases in the MSI 
colon cancers.
Tumors with MSI had a significantly higher number 
of CD3 + TILs in IM and CD8 + TILs in both TC and IM 
(Fig. 4). There was no significant association between high 
immune score and sex, median age, localization, grade, 
tumor size, N-status, tumor budding, lymphovascular or 
perineural infiltration.
Discussion
In this study, we present an objective automated, digital 
quantification method of CD3 + and CD8 + lymphocytes at 
IM and in TC in colon cancer. The resultant immune score 
is strongly associated with TNM stage and microsatellite 
instability, two well-documented and very strong prognostic 
factors in colon cancer. The immune score allowed to stratify 
patients into low, intermediate and high immune response 
groups. The quantification should be easy to use by other 
digital pathology laboratories and represent a robust and 
objective approach to immune cell quantification in colon 
cancer specimens.
The method is based on the construct principle of the 
“Immunoscore”, which has been validated in a large interna-
tional cohort series [11]. However, this commercially avail-
able  Immunoscore® (HalioDx, Marseille, France) is adapted 
to certain manufactures of antibodies and autostainer [11], 
and may prevents laboratories from setting up the method 
with available equipment in the laboratory. Widespread eval-
uation and dissemination may thus be hampered. Hence, the 
current quantification may represent an alternative measure-
ment that is adoptable, easy to implement, affordable and 
objective, yet provides transparency for reproduction.
We found that the number of TILs is significantly higher 
at the IM than in TC, corresponding to a previously reported 
study [35]. Furthermore, our study showed that patients with 
high immune score were associated with an earlier stage of 
the disease, which might explain why high immune score is 
associated with better prognosis. Several studies show that 
TILs play a significant role for prognosis in colon cancer. 
Mlecnik et al. found that a high density of CD8 + TILs is 
associated with reduced risk of relapse [35], whereas Angell 
and co-workers [36] found that tumors with reduced num-
bers of CD8 + had a higher risk of metastasis. A recent meta-
analysis of 22 studies including 5108 patients by Zhao and 
co-workers, found that high CD3 + infiltrates in colon can-
cer correlated with improved cancer-specific survival and 
overall survival. Furthermore, the same study found that 
high density of CD3 + in IM indicated increased disease-
free survival (DFS) and high CD8 + in TC was associated 
with improved DFS [37]. The abovementioned studies all 
support that scoring TILs in colon cancer can give valuable 
prognostic information.
In the NICHE study [38], the investigators explored the 
safety and efficiency of neoadjuvant immunotherapy (ipili-
mumab and nivolumab) in operable colon cancers. Despite 
being a small phase I/II study with over half being MSI 
cancer, a remarkable response was found (pathological 
response in 20/20 MSI patients; 19 had major pathological 
Table 2  Distribution of patients 
(n) with high immune response 
(≥ 75th percentile) in different 
regions
Tumor center Invasive margin
CD3 Low CD3 High CD8 Low CD8 High CD3 Low CD3 High CD8 Low CD8 High
0 of 4 69 0 69 0 69 0 69 0
1 of 4 13 1 12 2 9 5 8 6
2 of 4 5 9 5 9 8 6 10 4
3 of 4 3 8 3 8 3 8 2 9
4 of 4 0 11 0 11 0 11 0 11
Total 90 29 89 30 89 30 89 30
Table 3  Immune score based on high tumor density of CD3 and CD8 
in different regions
Number of regions Patients (n) Means of markers
0 of 4 69 Low
1 of 4 14
2 of 4 14 Intermediate
3 of 4 11 High
4 of 4 11
Total 119
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response and 12 had complete pathological response. Even 
in tumors with MSS, 4 of 15 had response [38]. As density 
of immune cells were related to response, a pre-treatment 
biopsy may become important. While not investigated in 
the NICHE study, the current template for immune score by 
digital pathology may become essential to select the patients 
who would benefit from such treatment in the future. Of 
note, half the patients in the NICHE study had MSI tumors, 
suggesting a selection of the included patients. The current 
rate of 35% MSI is high, but reflect that only colon (and no 
rectal) cancers were selected for the cohort and, is in line 
with previously reported data for such cohorts [39].
So far, and to the best of our knowledge, no biomark-
ers based on digital image analysis (DIA), has been used 
in pathological classification of colon cancer [24], despite 
digital pathology now being steadily introduced in routine 
diagnostic practice at several pathology departments. While 
there is a lack of consensus biomarkers for use, the imple-
mentation and spread in use makes it easier to use DIA in 
diagnostic setting and to perform prognostic scoring. For 
immune score to become an international recognized stand-
ard, it is important that it is available through affordable soft-
ware and that the method is transparent. Others have applied 
deep learning methods to analyze TILs in HE sections [40, 
41] and have found association with survival.
The added time and cost to stain and score relies on a 
couple of assumptions. One, a digital platform needs to be 
in place. We recognize that not all pathology labs may have 
this readily available, but increasingly this is being rolled 
out as the way forward to standardize scoring in quantitative 
pathology. Second, the time taken for a technician or bioen-
gineer to cut slides and prepare counts from the template is 
time efficient. If standardized and introduced into the routine 
pathway of clinical work, the estimated extra time for a bio-
engineer to cut, stain and prep for digital analysis would be 
in the range of 15–20 min; the pathologist’s time to mark the 
area for digital analyses would be part of the routine clini-
cal work and add a maximum of 30 min, but probably less. 
Hence, the use of this score should not be labor intensive nor 
require extensive human hours of labor.
The cost implied (given that digital pathology instruments 
are available in a given pathology lab) amounts to reagents 
for immunohistochemistry markers. These are usually avail-
able already in most labs, and in general inexpensive (esti-
mated at around 10 Euros per slide), but with variable costs 
between countries. Taken together, we believe that the tem-
plate for an automated immune score presented here would 
be both time efficient and cost containing.
Our study has some limitations to address, with one 
being the size of the cohort. A larger cohort size might have 
Fig. 4  Comparison of number of CD3 + and CD8 + tumor-infiltrating lymphocytes (TILs) of MSS and MSI tumors in tumor center (TC) and 
invasive margin (IM). Extreme values > 4000 cells is not shown in figure
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demonstrated more differences between the clinicopatho-
logical parameters in the patients to the high immune score 
versus the patients with intermediate and low immune score. 
Furthermore, the DIA method is not validated against manual 
pathology evaluation using a microscope and counting cells. 
This is near impossible (from a time and labour perspective 
implied) due to the high number of positive cells found in each 
tissue slide. However, the less time-consuming and labour-
efficient results obtained by DIA exemplifies the strength of 
using automated digital pathology to this extent. The interna-
tional effort of validating the “Immunoscore®” as a prognostic 
marker demonstrated value of the commercial test [11]. Future 
studies using easy-to-use, available, objective and reproduc-
ible methods to assess TILs in colon cancer may facilitate its 
wider dissemination and clinical implementation. With further 
validation, internally and externally, the role of the current 
template-based immune score should arrive at clinically rel-
evant use and be able to designate appropriate subgroups of 
patients stratified to their relevant therapy decisions.
Conclusion
A whole slide, digital pathology template using imaging 
software was developed to quantify immune score. Known 
clinicopathological features like MSI status correlated with 
a higher immune infiltrate, exemplified by a greater immune 
score. Large-scale internal and external validation to dem-
onstrate robustness and generalizability for clinical use is 
ongoing.
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